Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Feb 9 2024

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

February 9, 2024


Chicago, IL 60612

Funding Opportunity Purpose

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Key Dates

Posted Date
March 30, 2021
Open Date (Earliest Submission Date)
July 10, 2021
Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Date(s)

August 10, 2021, February 9, 2022, August 9, 2022, February 9, 2023, August 9, 2023, February 9, 2024

For more information, click here


Ann-Marie Broome PhD MBA

Date posted

Apr 8, 2021

Date updated

Apr 8, 2021